Wegovy maker Novo Nordisk said it is teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company’s platform, bringing an end to a legal dispute between the two ...

"We have decided to drop the current court proceedings," Novo CEO Mike Doustdar told CNBC on Monday, however, reserving the right to bring it back "if needed." It comes after an agreement between Novo ...

The weight-loss drugs that kicked off America's GLP-1 craze are about to get a lot less expensive, though only certain customers will notice the savings. Novo Nordisk said it will slash list prices of ...

Novo Nordisk’s experimental weekly shot CagriSema was shown to lead to less dramatic weight loss compared to rival Lilly’s Tirzepatide, the drug behind Zepbound and Mounjaro, in an 84-week trial, Novo ...

Novo's drug, CagriSema, didn't achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly's rival drug tirzepatide. The stock plummeted on Monday, hitting its ...

Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers it’s lost to rival Eli Lilly & Co. Currently Novo sells the drug in plastic ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving patients and putting their health at risk” by selling compounded versions of ...

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knock-offs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Novo on Monday argued ...

Novo Nordisk A/S said it’s suing Hims & Hers Health Inc. for making knockoffs of its obesity medicines, even as Hims scrapped plans to sell a copycat version of the Wegovy pill. Hims is breaching the ...

Hims & Hers (HIMS) on Monday called a patent lawsuit filed by Novo Nordisk (NVO) over IP rights linked to the Danish drugmaker’s weight loss therapy, semaglutide, “a blatant attack” targeting ...